FDA Modernization Act 3.0
Senate Passes FDA Modernization Act 3.0, Expanding Drug Testing Beyond Animal-Only Experiments
Legislative Progress
Key Points
- Tells the Food and Drug Administration to quickly update its rules so drug companies are not locked into using only animal tests before human trials
- Changes the wording in many drug approval rules so they say “nonclinical tests” instead of only “animal tests,” opening the door to lab-grown tissue, computer models, and other newer methods
- Keeps drug safety rules in place but lets companies choose from more modern testing tools that may be faster, cheaper, and use fewer animals
- Orders these updates to take effect quickly, without long delays, so the law passed in 2023 about new testing methods can actually be used in real drug applications
- Could, over time, speed up how new medicines and vaccines reach patients by making the early testing stage more flexible
Impact Analysis
Personal Impact
How this policy affects specific groups of people
Milestones
Held at the desk.
Received in the House.
The House has received the Senate-passed bill and will decide whether to take it up.
Message on Senate action sent to the House.
Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S8794)
The Senate voted to approve this bill. If the House already passed it, it goes to the President.
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.
The Senate voted to approve this bill. If the House already passed it, it goes to the President.
Votes
No votes have been recorded for this legislation yet.
Related News
4 articlesFDA plans to phase out animal testing requirements
The FDA announced it will begin phasing out animal testing requirements for antibody therapies and other drugs, moving toward AI-based models and 'human-relevant' tools. The move follows the legislative push from the FDA Modernization Act to reduce reliance on costly and often inaccurate animal models.
FDA moves to phase out animal tests for certain new drugs
FDA Commissioner Marty Makary announced a shift away from animal testing, a move directed by recent federal law. The agency will focus on monoclonal antibodies first, aiming to get treatments to patients faster while sparing primates and dogs from experiments.
FDA takes steps to reduce animal testing requirements for monoclonal antibodies
The FDA announced plans to replace animal testing with AI-based computational modeling and human organ model-based lab testing. This approach follows the introduction of the FDA Modernization Act 3.0, intended to shore up implementation of previous reforms and reduce drug development costs.
Source Information
Document Type
Congressional Bill
Official Title
FDA Modernization Act 3.0
Data Sources
Sponsor
Cosponsors
(9)Analysis generated by AI. Always verify with official sources.